Holen Sie sich die Stockscreener-App
58.73
0.17%
-0.10
Schlusskurs vom Vortag:
$58.83
Offen:
$58.83
24-Stunden-Volumen:
1.52M
Relative Volume:
0.43
Marktkapitalisierung:
$26.03B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
30.76
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
+2.50%
1M Leistung:
+4.45%
6M Leistung:
+44.16%
1J Leistung:
+60.16%
1-Tages-Spanne:
$58.49
$59.41
1-Wochen-Bereich:
$56.90
$59.72
52-Wochen-Spanne:
$34.08
$59.72
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.73 | 26.03B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Renaissance Technologies LLC Buys Shares of 790,937 Royalty Pharma PLC $RPRX - MarketBeat
First Trust Advisors LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD - TradingView
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RPRX|Royalty Pharma PLC|Price:58.730|Chg%:-0.100 - TradingKey
Royalty Pharma PLC (RPRXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Dorsey Asset Management LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD - TradingView
Royalty Pharma PLC (RPRXN) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Shares Sold by KBC Group NV - MarketBeat
RPHC5035520 Bond Profile — Key Metrics - TradingView
ABN Amro Investment Solutions Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Earnings Dates, Call Summary & Reports - TipRanks
RPHC6166014 Bond Profile — Key Metrics - TradingView
Royalty Pharma PLC (RPRX) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
RPHC5222528 Bond Profile — Key Metrics - TradingView
RPHC6166014 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5035520 Bond Risk Profile - TradingView
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237354 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Royalty Pharma PLC (RPRX) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - 富途牛牛
Royalty Pharma PLC (RPRXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):